New drug aims to stop breast cancer return in High-Risk patients
NCT ID NCT07242352
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether the drug elacestrant can help prevent breast cancer from coming back in people with high-risk HR+/HER2- early breast cancer. About 1,520 participants will receive either elacestrant or standard hormone therapy for up to 7.5 years. The study compares how long people live without their cancer returning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elacestrant (a hormone therapy drug)
What this could lead to
If successful, this could offer a more effective hormone therapy option for people with high-risk early breast cancer, potentially reducing the chance of cancer returning.
What could go wrong
This is a large Phase 3 trial, but results are not yet known. Elacestrant may not prove better than current treatments, and side effects are possible. The study is still recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus
RECRUITINGMönchengladbach, North Rhine-Westphalia, 41061, Germany
Contact
Contact
Contact